These studies suggested that ccf-mtDNA is a potential tumor molecular marker, and our study further verified that ccf-mtDNA content in serum samples could be a potential non-invasive prognostic biomarker for HCC patients. This evidence concerns the gene PITX1 and hepatocellular carcinoma.